BIOLASE, Inc. (BIOLQ)
OTCMKTS
· Delayed Price · Currency is USD
0.0090
-0.0045 (-33.48%)
Apr 4, 2025, 4:00 PM EST
BIOLASE Revenue
BIOLASE had revenue of $10.85M in the quarter ending September 30, 2024, a decrease of -0.65%. This brings the company's revenue in the last twelve months to $46.03M, down -7.44% year-over-year. In the year 2023, BIOLASE had annual revenue of $49.16M with 1.45% growth.
Revenue (ttm)
46.03M
Revenue Growth
-7.44%
P/S Ratio
0.01
Revenue / Employee
293.16K
Employees
157
Market Cap
395.25K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 49.16M | 702.00K | 1.45% |
| Dec 31, 2022 | 48.46M | 9.27M | 23.67% |
| Dec 31, 2021 | 39.19M | 16.41M | 72.03% |
| Dec 31, 2020 | 22.78M | -15.02M | -39.73% |
| Dec 31, 2019 | 37.80M | -8.36M | -18.10% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 16.04M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.38M |
| American Oncology Network | 1.76B |
| Longduoduo Company | 6.01M |